Coxsackievirus Infections

BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, announced today its unaudited financial results for the six months ended June 30, 2023. First Half of 2023 Financial Summary Sales for the six months ended June 30, 2023 were $140.4 million, compared to $1.2 billion in the prior year period. The Company posted $14.0 million of net income attributable to common shareholders, or $0.14 per basic and $0.15 per diluted share, in the six-month period ended June 30, 2023, compared to net income attributable to common shareholders of $481.6 million, or $4.84 per basic and $4.24 per diluted share, in the prior year period. Mr. Weidong Yin, Chairman, President and CEO of SINOVAC, commented “After experiencing three years of the COVID-19 pandemic, the world is still facing the threat of various infectious diseases in 2023. The ability to combat global outbreaks remains vital to world health. As a prominent biopharmaceutical products provider in China, SINOVAC continues to increase its investment in the research and development and production of vaccines beyond COVID-19, and keeps exploring additional biomedical products including antibodies. Meanwhile, we maintained a strong international presence, by providing high-quality vaccines and localized production. “Looking ahead, SINOVAC is determined to sustain our business momentum in both domestic and international markets, strengthen our product portfolio and partnerships, and provide many accessible pharmaceutical products to meet the increasing healthcare demand from around the world.” Business Updates COVID-19 Antibody Products – SINOVAC’s broad-spectrum neutralizing antibody products, SA55 Injection and Nasal Spray, which are intended for the prevention and treatment of COVID-19 infections, were approved for clinical trial in China. By leveraging its extensive experience in COVID-19 vaccine development and production, SINOVAC is capable of large-scale manufacture of these broad-spectrum neutralizing antibody products in compliance with Good Manufacturing Practice standards. Hepatitis A Vaccine – Healive®, the first and only WHO prequalified inactivated hepatitis A vaccine from China, has been registered in more than 20 countries and organizations worldwide by thus far, with additional market approvals in Lebanon, Kyrgyzstan, Egypt, India and Pakistan this year. Influenza Vaccine – A new and state-of-the-art influenza vaccine production line started operations in Beijing. The plant, which complies with Chinese Good Manufacturing Practice guidelines and utilizes green production processes, enables automated production at scale that expands SINOVAC capacity to meet the growing global demand for high-quality influenza vaccines. SINOVAC’s influenza vaccines expand international market accessibility in the first half of 2023 by gaining more overseas market approvals, such as Pakistan and Chile. Varicella Vaccine – SINOVAC’s live attenuated varicella vaccine, the first WHO prequalified Chinese varicella vaccine, successfully delivered to the Republic of Türkiye early this year. The vaccine was also registered in Lebanon and Kenya this year. Hand Foot and Mouth Disease Vaccine – SINOVAC’s bivalent inactivated vaccine, developed to combat enterovirus (EV) and coxsackievirus (CV) infections, was approved for clinical trials in China this year. It aims to protect children from hand, foot and mouth disease caused by EV71 and CA16. SINOVAC’s EV 71 vaccine, Inlive®, has already safeguarded millions of children in China. Strategic Development outside of China - SINOVAC has been named the exclusive strategic partner of BogotáBio, which will break ground as the first local human vaccine production facility to be established with local government in Colombia’s capital city of Bogota. SINOVAC's extensive expertise and experience in vaccine R&D and production, and successful track record establishing vaccine manufacturing facilities will play a pivotal role in the new venture. Unaudited Financial Results for the First Half of 2023 Sales for the first half of 2023 were $140.4 million, compared to $1.2 billion in the prior year period. The decrease was mainly due to decreased sales of CoronaVac®. The negative gross margin at 34.2% was caused by the sharply reduced sales of CoronaVac combined with the COVID-19 employee incentive plan established in 2022. Selling, general and administrative expenses in the first half of 2023 were $231.0 million, compared to $155.9 million in the prior year period. The increase was mainly due to a COVID-19 employee incentive plan established in 2022. R&D expenses in the first half of 2023 were $151.1 million, compared to $184.4 million in the prior year period. Net loss in the first half of 2023 was $30.0 million, compared to net income of $790.4 million in the prior year period. Net income attributable to common shareholders was $14.0 million, or $0.14 per basic and $0.15 per diluted share, in the first half of 2023, compared to a net income attributable to common shareholders of $481.6 million, or $4.84 per basic and $4.24 per diluted share, in the prior year period. As the Company announced on February 22, 2019, the Company’s board of directors determined that certain shareholders became acquiring persons, as defined in the Company’s rights agreement (“Rights Agreement”), under which a trigger event occurred. As a result, the Company issued new common and preferred shares of SINOVAC. Without the effect of implementing the Rights Agreement and newly-issued common and preferred shares, basic and diluted earnings per share for the first half of 2023 would be $0.24 and $0.24, respectively. Non-GAAP adjusted EBITDA was $346.6 million loss in the first half of 2023, compared to $691.3 million income in the prior year period. Non-GAAP net loss was $120.9 million in the first half of 2023, compared to $628.8 million net income in the prior year period. Non-GAAP diluted earnings per share in the first half of 2023 was negative $0.32 compared to $3.41 per share in the prior year period. Non-GAAP diluted earnings per share in the first half of 2023, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be negative $0.51. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this news release. As of June 30, 2023, cash and cash equivalents and restricted cash totaled $1.6 billion, compared to $4.3 billion as of December 31, 2022. In the first half of 2023, net cash used in operating activities was $40.0 million, net cash used in investing activities was $2.7 billion reflecting the net position of short-term investment purchase over redemption, and net cash provided by financing activities was $217.2 million. The Company’s first half of 2023 financial statements are prepared and presented in accordance with U.S. GAAP. However, they have not been audited or reviewed by the Company’s independent registered accounting firm. Legal Proceedings As previously disclosed by the Company, on March 13, 2018, 1Globe Capital LLC (“1Globe”) filed a complaint against the Company in the Antigua Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his judgment (the “Antigua Judgment”), finding the Company fully in favor, dismissing 1Globe’s claim and declaring the Rights Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe’s rights or shareholding or otherwise distributing the exchange shares to the Company’s shareholders who did not trigger the Rights Plan until after the determination of the appeal (the “Exchange Shares”). 1Globe’s appeal against the Antigua Judgment was heard on September 18, 2019, and the appeal decision was announced by the Eastern Caribbean Supreme Court, Court of Appeal (the “Court of Appeal”) on December 9, 2021, upholding the Antigua Judgment in each point. 1Globe applied for leave to appeal to the Judicial Committee of the Privy Council (the “Privy Council”), and the hearing of the application was held on February 24, 2022, in which the Court of Appeal granted 1Globe leave to appeal to the Privy Council on certain grounds, although not including the challenge to the validity of the Rights Agreement. On April 19, 2022, 1Globe renewed its application directly to the Privy Council for leave to appeal on its ground of appeal concerning the validity of the Rights Agreement. On July 13, 2022, 1Globe filed its Notice of Appeal on those grounds on which the Court of Appeal had granted 1Globe leave to appeal. On September 16, 2022, 1Globe filed an application to the Privy Council seeking permission to amend its existing application for permission to appeal and its existing Notice of Appeal, and to seek permission to appeal on another ground rejected by the Court of Appeal concerning the exercise of the Antigua Court’s discretion. SINOVAC responded on October 21, 2022. On February 15, 2023, the Privy Council made a procedural decision to allow amendment of its existing application for permission to appeal, and decided to deal with procedural and substantive issues together at the Final Hearing. 1Globe is still completing necessary procedural filings, and has not yet taken steps to list a substantive hearing before the Privy Council. The appeal outcome is therefore pending. As previously disclosed, on March 5, 2018, SINOVAC filed a lawsuit in the Court of Chancery of the State of Delaware, seeking a determination on whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC and certain other shareholders of the Company had triggered the Rights Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company’s complaint, counterclaims and a third-party complaint against the Company and Mr. Weidong Yin, alleging, among other allegations, that the Rights Agreement is not valid. On March 6, 2019, the Delaware Chancery Court entered a status quo order, providing that the Company not distribute any of the Exchange Shares to the Company’s shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or further order of the Court. On April 8, 2019, the Delaware Chancery Court stated that the Delaware litigation was pending the final outcome of 1Globe’s appeal of the Antigua Judgment. Separately, Heng Ren Investments LP (“Heng Ren”) filed suit against SINOVAC and Weidong Yin for alleged breach of fiduciary duties and wrongful equity dilution on May 31, 2019, in Massachusetts state court. SINOVAC moved the matter from state court to the United States District Court for the District of Massachusetts. On September 14, 2020, SINOVAC filed a motion to dismiss Heng Ren’s claims. Subsequently, on April 29, 2021, Heng Ren filed an amended complaint which alleged that Mr. Yin breached fiduciary duties owed to minority shareholders, that SINOVAC aided and abetted breaches of fiduciary duties, and that both SINOVAC and Mr. Yin engaged in wrongful equity dilution. Heng Ren requested damages, attorneys’ fees, and prejudgment interest. On July 16, 2021, SINOVAC moved to dismiss Heng Ren’s amended complaint in the federal court in Massachusetts. On March 4, 2022, the court granted the motion as to the breach of fiduciary duty claims and denied the motion as to the wrongful equity dilution claim, and denied reconsideration of its decision on the motion. SINOVAC has answered the complaint. On January 19, 2023, SINOVAC filed a motion to stay the Heng Ren action pending the resolution of a putative shareholder class action, described in the paragraph below. On February 15, 2023, the court stayed discovery in the Heng Ren matter pending the resolution of the putative class action. As previously disclosed by the Company, On December 5, 2022, a purported shareholder filed a putative class action complaint in United States District Court for the District of Massachusetts, asserting a claim under Section 204 of the Antigua and Barbuda International Business Corporations Act related to a private placement of SINOVAC’s common shares with private investors Vivo Capital and Advantech Capital completed on July 2, 2018 (the “PIPE Transaction”), alleging that all shareholders were harmed in an identical manner to one another by the PIPE Transaction because the shares that were issued in the PIPE transaction allegedly undervalued SINOVAC and all shareholders were purportedly wrongfully diluted as a result. The purported shareholder is represented by the same attorney who represents Heng Ren, and requests damages, attorneys’ fees, and prejudgment interest. On January 18, 2023, SINOVAC filed a motion to dismiss. The motion was fully briefed as of March 9, 2023, and is currently pending before the court. Status of Exchange Shares and Trading in the Company’s Shares As a result of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company’s shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgement and the final disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding. The Nasdaq Stock Market LLC implemented a halt on trading of the Company’s common shares at the time the Exchange Shares were issued to the trust. The Company is currently unable to estimate when trading will resume, or if Nasdaq will take any additional action in regards to trading of the Company’s common shares. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of biomedical products that protect against human diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to pipeline development including but not limited to new technology, new vaccines as well as other biomedical products. We will constantly explore global opportunities of strategic expansion. For more information, please visit the Company’s website at . Safe Harbor Statement This press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan. Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with GAAP, SINOVAC uses the following non-GAAP financial measures: non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS. For more information on these non-GAAP financial measures, please refer to the table captioned “Reconciliations of non-GAAP Measures to the Nearest Comparable GAAP Measures” in this results announcement. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS help identify underlying trends in its business that could otherwise be distorted by the effect of certain income or expenses that SINOVAC includes in net income and diluted EPS. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS provide useful information about its core operating results, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making. Non-GAAP adjusted EBITDA, non-GAAP net income and non-GAAP diluted EPS should not be considered in isolation or construed as an alternative to income from operations, net income, diluted EPS, or any other measure of performance or as an indicator of SINOVAC’s operating performance. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. Non-GAAP adjusted EBITDA represents net income and excludes interest and financing expenses, interest income, net other income and income tax benefit (expenses), and certain non-cash expenses, consisting of share-based compensation expenses, amortization and depreciation that SINOVAC does not believe are reflective of the core operating performance during the periods presented. Non-GAAP net income represents net income before share-based compensation expenses and foreign exchange gain or loss. Non-GAAP diluted EPS represents non-GAAP net income attributable to common shareholders divided by the weighted average number of shares outstanding during the periods on a diluted basis, including accounting for the effect of the assumed conversion of options. SINOVAC BIOTECH LTD. Consolidated Balance Sheets As of June 30, 2023 and December 31, 2022 (Expressed in thousands of U.S. Dollars) June 30, 2023 December 31, 2022 Current assets Cash and cash equivalents $ 1,643,026 $ 4,278,124 Restricted cash 3,734 8,253 Short-term investments 9,425,778 7,034,569 Accounts receivable - net 425,245 537,118 Inventories 182,735 180,719 Prepaid expenses and deposits 13,312 15,242 Income tax receivable 75,195 72,371 Total current assets 11,769,025 12,126,396 Property, plant and equipment – net 1,058,962 993,781 Prepaid land lease payments 65,519 69,815 Intangible assets - net 8,753 9,699 Long-term prepaid expenses 22 23 Long-term investments 657,767 661,440 Prepayments for acquisition of equipment 16,292 120,912 Deferred tax assets 98,688 71,118 Right-of-use assets 47,676 58,586 Other Non-current Assets 2,306 2,798 Total assets 13,725,010 14,114,568 Current liabilities Short-term bank loans and current portion of long-term bank loans 201,118 293 Loan from a non-controlling shareholder 4,159 4,358 Accounts payable and accrued liabilities 819,530 905,923 Deferred revenue 15,153 17,955 Deferred government grants 4,132 15,120 Dividend payable 139,547 141,993 Lease liability 5,990 5,993 Total current liabilities 1,189,629 1,091,635 Deferred government grants 6,548 4,477 Long-term bank loans 10,989 11,513 Deferred tax liability 239,029 241,526 Lease liability 40,929 52,516 Other non-current liabilities 630 240 Total long-term liabilities 298,125 310,272 Total liabilities 1,487,754 1,401,907 Commitments and contingencies Equity Preferred stock 15 15 Common stock 100 100 Additional paid-in capital 541,258 540,582 Accumulated other comprehensive loss (654,462) (383,276) Statutory surplus reserves 1,538,013 1,538,013 Accumulated earnings 7,239,947 7,225,987 Total shareholders' equity 8,664,871 8,921,421 Non-controlling interests 3,572,385 3,791,240 Total equity 12,237,256 12,712,661 Total liabilities and equity $ 13,725,010 $ 14,114,568 SINOVAC BIOTECH LTD. Consolidated Statements of Comprehensive Income For the six months ended 2023 and 2022 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended June 30 2023 2022 Sales $ 140,404 $ 1,212,290 Cost of sales 188,409 254,362 Gross profit (loss) (48,005) 957,928 Selling, general and administrative expenses 231,048 155,880 Provision for doubtful accounts 386 807 Research and development expenses 151,132 184,394 Loss on disposal of property, plant and equipment 312 3,286 Government grants recognized in income (92) (14) Total operating expenses 382,786 344,353 Operating income (loss) (430,791) 613,575 Interest and financing expenses (264) (623) Interest income 29,589 83,998 Other income, net 337,856 229,458 Income (Loss) before income taxes (63,610) 926,408 Income tax benefit (expense) 33,597 (135,962) Net income (loss) (30,013) 790,446 Less: (income) loss attributable to non-controlling interests 46,931 (305,934) Net income attributable to shareholders of Sinovac 16,918 484,512 Preferred stock dividends (2,958) (2,958) Net income attributable to common shareholders of Sinovac 13,960 481,554 Net income (loss) (30,013) 790,446 Other comprehensive income, net of tax of nil Foreign currency translation adjustments (441,560) (579,251) Comprehensive income (loss) (471,573) 211,195 Less: comprehensive (income) loss attributable to non- controlling interests 217,305 (74,774) Comprehensive income (loss) attributable to shareholders of Sinovac (254,268) 136,421 Earnings per share Basic net income per share 0.14 4.84 Diluted net income per share 0.15 4.24 Weighted average number of shares of common stock outstanding Basic 99,576,600 99,502,243 Diluted 114,227,276 114,172,782 SINOVAC BIOTECH LTD. Consolidated Statements of Cash Flows For the six months ended 2023 and 2022 (Expressed in thousands of U.S. Dollars) Six months ended June 30 2023 2022 Operating activities Net income (loss) $ (30,013) $ 790,446 Adjustments to reconcile net income to net cash provided by operating activities: Deferred income taxes (32,124) (15,837) Inventory provision 12,624 56,203 Provision for doubtful accounts 386 807 Loss on disposal of property, plant and equipment 312 3,286 Depreciation of property, plant and equipment 82,484 75,159 Amortization of prepaid land lease payments 1,138 2,503 Amortization of intangible assets 527 97 Government grants recognized in income (92) (14) Loss from equity method investments 374 - Investment income (75,612) - Changes in: Accounts receivable 90,434 (140,015) Inventories (23,296) 37,251 Other non-current assets 2,785 - Income tax payable (5,824) (1,083,624) Prepaid expenses and deposits 1,583 133,914 Deferred revenue (2,074) (45,121) Accounts payable and accrued liabilities (47,208) (622,923) Deferred government grants (16,813) - Other non-current liabilities 418 (298) Net cash used in operating activities (39,991) (808,166) Financing activities Proceeds from bank loans 209,587 199 Repayments of bank loans (150) (3,038) Proceeds from issuance of common stock, net of share issuance costs 676 - Dividend paid to non-controlling shareholders (1,616) (2,469) Proceeds from subsidiary's financing 12,000 Government grants received 8,668 5,021 Repayments of loan from a non-controlling shareholder (1) (12) Net cash provided by financing activities 217,164 11,701 Investing activities Purchase of short-term investments (6,628,110) (15,123,334) Proceeds from redemption of short-term investments 4,013,372 11,890,425 Proceeds from disposal of equipment 37 603 Prepaid land lease payments - (9,658) Acquisition of property, plant and equipment (92,942) (279,398) Acquisition of intangible assets - - Purchase of long-term investments (24,792) (63,280) Distributions of equity method investees 1,342 - Proceeds from sale or maturity of long-term investments 146 Net cash used in investing activities (2,730,947) (3,584,642) Effect of exchange rate changes on cash and cash equivalents and restricted cash (85,843) (371,559) Decrease in cash and cash equivalents and restricted cash (2,639,617) (4,752,666) Cash and cash equivalents and restricted cash, beginning of period 4,286,377 (3,584,642) Cash and cash equivalents and restricted cash, end of period 1,646,760 (8,337,308) SINOVAC BIOTECH LTD. Reconciliations of Non-GAAP measures to the nearest comparable GAAP measures For the six months ended 2023 and 2022 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended June 30 2023 2022 (Unaudited) (Unaudited) Net income (loss) $ (30,013) $ 790,446 Adjustments: Depreciation and amortization 84,149 77,759 Interest income, net of interest and financing expenses (29,325) (83,375) Other income, net (337,856) (229,458) Income tax benefit (expense) (33,597) 135,962 Non-GAAP adjusted EBITDA (346,642) 691,334 Net income (loss) (30,013) 790,446 Less: Foreign exchange gain (90,851) (161,619) Non-GAAP net income (loss) (120,864) 628,827 Net income attributable to common shareholders of Sinovac 13,960 481,554 Add: Preferred stock dividends 2,958 2,958 Net income attributable to common shareholders of Sinovac for computing diluted earnings per share 16,918 484,512 Add: Non-GAAP adjustments to net income (53,349) (95,093) Non-GAAP net income attributable to common shareholders of Sinovac for computing non-GAAP diluted earnings per share (36,431) 389,419 Weighted average number of shares on a diluted basis 114,227,276 114,172,782 Diluted earnings per share 0.15 4.24 Add: Non-GAAP adjustments to net income per share (0.47) (0.83) Non-GAAP diluted earnings per share (0.32) 3.41 ​ View source version on businesswire.com: Contacts Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279 9720 Email: ir@sinovac.com Source: Sinovac Biotech Ltd. ​ View this news release online at:

A team of scientists has made an important breakthrough in the fight against RNA viruses that cause human diseases and pandemics. A team of scientists from A*STAR's Genome Institute of Singapore (GIS) and the Yong Loo Lin School of Medicine, National University of Singapore (NUS Medicine) has made an important breakthrough in the fight against RNA viruses that cause human diseases and pandemics. Their research shows that the CRISPR-Cas13 editor delivered by adeno-associated virus (AAV) can directly target and eliminate RNA viruses in laboratory models. AAV are delivery vehicles derived from small viruses that naturally infect humans.They are clinically approved for use in gene therapy drugs which are used to treat diseases such as spinal muscular atrophy, Duchenne muscular dystrophy, and haemophilia. The EV-A71 virus is the cause of the hand, foot, and mouth disease, and in severe cases, can lead to nervous system disease and death. To treat the viral infection, the team turned to CRISPR-Cas13, an RNA-editing technology that alters RNA in a cell. CRISPR-Cas13 edits RNA and opens therapeutic avenues to a wide range of diseases that are untreatable by the Nobel Prize-winning CRISPR-Cas9, which edits DNA. CRISPR-Cas13 is programmed by guide RNAs (gRNAs) to target specific RNA sequences. Upon binding to these RNA sequences, the CRISPR-Cas13 cuts the RNA target into pieces, inactivating the RNA. CRISPR-Cas13 could also be utilised for RNA-editing, where a specific RNA sequence is changed to another sequence within the cell. In this recent work, the team of scientists first developed the Cas13gRNAtor computational programme to design CRISPR gRNAs that cut viral RNA across different viral strains. They show that CRISPR-Cas13 treatment potently reduces viral burden, with less than 0.1% of the viruses remaining in previously infected cells. Importantly, the research findings show that the AAV-CRISPR-Cas13 therapy clears the EV-A71 infection and prevents organ damage and mortality. "This is a stunning demonstration that one dose of CRISPR-Cas13 can mean a difference between life and death. We are building on this research to develop further life-changing nucleic acid therapeutics." said Dr Chew Wei Leong, Associate Director and Principal Scientist at A*STAR's GIS. Associate Professor Justin Chu from NUS Medicine's Department of Microbiology and Immunology and Infectious Diseases Translational Research Programme added, "This amazing study has helped to unlock the new frontiers in antiviral strategies by using AAV-CRISPR-Cas13 to combat human enteroviruses, paving the way for potential therapeutics against viral diseases." Professor Liu Jian Jun, Acting Executive Director of A*STAR's GIS said, "The CRISPR technology allows the rewriting of the genetic code in almost any organism. This joint research with NUS is an extremely important development which can potentially treat many diseases caused by RNA viruses, and open many avenues for further therapeutic solutions." These findings demonstrate a therapeutic development pipeline for antiviral AAV-CRISPR-Cas13 against potentially deadly RNA virus infections. Further therapeutic development could bring this technology towards treating human RNA viruses in the clinic. This research was published on 28 June 2023, in eBioMedicine, part of The Lancet Discovery Science.

BEIJING--(BUSINESS WIRE)-- Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, has filed its 2022 annual report on Form 20-F with the U.S. Securities and Exchange Commission for the year ended December 31, 2022. The Company also reported its unaudited financial for the second half and audited financial for full year ended December 31, 2022. Second Half and Full Year 2022 Financial Summary Sales for the six months ended December 31, 2022 were $280.5 million, compared to $8.4 billion in the prior year period. Sales in 2022 were $1.5 billion, compared to $19.4 billion in the prior year. The Company posted $373.7 million of net loss attributable to common shareholders, or a loss of $3.76 per basic and diluted share, in the six months ended December 31, 2022, compared to net income attributable to common shareholders of $3.4 billion, or $33.79 per basic and $29.46 per diluted share, in the prior year period. The Company posted $107.9 million of net income attributable to common shareholders, or $1.08 per basic and $1.00 per diluted share in 2022, compared to net income attributable to common shareholders of $8.5 billion, or $85.20 per basic and $74.27 per diluted share, in the prior year period. Mr. Weidong Yin, Chairman, President and CEO of SINOVAC, commented “In 2022, we significantly increased our R&D investment and expanded our global market reach. Our R&D investment nearly tripled, and we are developing various vaccines to prevent over 20 life-threatening diseases. Growth was maintained in our non-covid business in 2022. We keep executing our business strategy of expanding our regular business into international market. More than 10 countries granted licenses to our non-COVID vaccines. In addition, our varicella vaccine and sIPV were successfully passed WHO prequalification assessment in 2022. “Looking ahead into 2023, we remain confident in our comprehensive product portfolio and growing business and scientific partnerships. Our mission to ‘supply vaccines to eliminate human diseases’ remains at the forefront, and we are committed to achieving this goal by investing in cutting-edge technology, expanding our global partnerships, and increasing accessibility to our life-saving vaccines,” Mr.Yin added. Business Updates COVID-19 Vaccine – CoronaVac®, the inactivated COVID-19 vaccine developed by SINOVAC, has been approved for use in more than 60 countries and regions worldwide. At this time, over 2.9 billion doses of CoronaVac® have been delivered globally, making SINOVAC the largest China-based COVID-19 vaccine provider to the international market. CoronaVac® has been validated by the World Health Organization ("WHO") for extended use in children as young as three years old under the Emergency Use Listing ("EUL") Procedure, in November 2022. This is the youngest age that the WHO has validated for EUL of COVID-19 vaccines in the world so far. CoronaVac® has also been fully registered in Hong Kong under the Pharmacy and Poisons Ordinance Cap 138 in December 2022, as one of the first COVID-19 vaccines approved for such official registration in Hong Kong. Since then, the vaccine can be supplied to registered medical practitioners and institutions for both private and public markets in Hong Kong. In 2022, the results of sufficient real-world studies and clinical trials in various regions and countries confirmed the safety and effectiveness of CoronaVac® for pediatric and adolescent populations, as well as demonstrated that the vaccine was effective in preventing multiple Omicron waves, particularly for individuals over the age of 60 who received three doses of the vaccine. Influenza Vaccines – Quadrivalent Influenza Vaccine, the latest development of SINOVAC's influenza vaccine family, entered the global market in 2022 by gaining overseas commercialization approvals. In 2022, the influenza vaccines became SINOVAC’s highest revenue generating non-COVID product for the first time. Recently, a new and state-of-the-art influenza vaccine production facility of SINOVAC started operations in Beijing. The plant, which complies with Chinese Good Manufacturing Practice (GMP) guidelines and utilizes green production processes, enables automated production at scale that expands SINOVAC capacity to meet the growing global demand for high-quality influenza vaccines. Varicella Vaccine – the live attenuated varicella vaccine was prequalified by the WHO in November 2022, marking the first WHO prequalified Chinese varicella vaccine, and received its first overseas order in 2022. Hepatitis A Vaccine – Healive®, the first and only WHO prequalified hepatitis A vaccine from China, has been registered in 24 countries and organizations worldwide thus far. Inactivated Enterovirus Type 71 (EV71) Vaccine – Inlive®, has been authorized for children between the ages of six months to three-years-old by BPOM, the food and drug agency of Indonesia, in November 2022, which is the first vaccine approved in Indonesia to protect from hand, foot and mouth diseases (HFMD). This is also Inlive®'s first overseas authorization. Sabin Inactivated Polio vaccine (“sIPV”) – the Poliomyelitis Vaccine (Vero Cell), Inactivated, Sabin Strains, was prequalified by WHO in June 2022, and sIPV is available for United Nations (UN) agencies to purchase to support the global polio eradication strategy. Quality Control – Two quality control laboratories in SINOVAC have been accredited by the China National Accreditation Service for Conformity Assessment (CNAS) in 2022. Unaudited Financial Results for the Second Half of 2022 Sales for the second half of 2022 were $280.5 million, compared to $8.4 billion in the prior year period. The decrease was mainly due to decreased sales of CoronaVac®. Selling, general and administrative expenses in the second half of 2022 were $667.7 million, compared to $428.5 million in the prior year period. R&D expenses in the second half of 2022 were $257.7 million, compared to $101.1 million in the prior year period. Net loss in the second half of 2022 was $702.3 million, compared to net income of $5.9 billion in the prior year period. Net loss attributable to common shareholders was $373.7 million, or a loss of $3.76 per basic and diluted share, in the second half of 2022, compared to a net income attributable to common shareholders of $3.4 billion, or $33.79 per basic and $29.46 per diluted share, in the prior year period. As the Company announced on February 22, 2019, the Company’s Board of Directors determined that certain shareholders became acquiring persons, as defined in the Company’s rights agreement (“Rights Agreement”), under which a trigger event occurred. As a result, the Company issued new common and preferred shares of SINOVAC. Without the effect of implementing the Rights Agreement and newly-issued common and preferred shares, basic and diluted loss per share for the second half of 2022 would be $5.17. Non-GAAP adjusted EBITDA was $1.0 billion loss in the second half of 2022, compared to $7.5 billion in the prior year period. Non-GAAP net loss was $805.8 million in the second half of 2022, compared to $5.9 billion net income in the prior year period. Non-GAAP diluted loss per share in the second half of 2022 was $3.79 compared to an earnings per share of $29.87 in the prior year period. Non-GAAP diluted loss per share in the second half of 2022, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $6.02. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement. The Company’s second half of 2022 financial statements are prepared and presented in accordance with U.S. GAAP. However, they have not been audited or reviewed by the Company’s independent registered accounting firm. Financial Results for the Twelve Months Ended December 31, 2022 Sales in 2022 were $1.5 billion, a decrease from $19.4 billion in the prior year. The decrease was due to decreased sales of CoronaVac®. Selling, general and administrative expenses in 2022 were $823.5 million, compared to $591.2 million in the prior year. R&D expenses in 2022 were $442.1 million, compared to $155.0 million in the prior year. The Company continued to invest in the advancement of pipeline vaccines. Net income in 2022 was $88.1 million, compared to $14.5 billion in the prior year. Net income decreased primarily due to decreased sales. Net income attributable to common shareholders was $107.9 million, or $1.08 per basic and $1.00 per diluted share, compared to net income attributable to common shareholders of $8.5 billion, or $85.20 per basic and $74.27 per diluted share, in the prior year. Excluding the implementation of the Rights Agreement, as described above, and the newly-issued common and preferred shares, basic and diluted earnings per share for 2022 would be $1.59. Non-GAAP adjusted EBITDA was $309.5 million loss in 2022, compared to income of $17.6 billion in the prior year. Non-GAAP net loss in 2022 was $177.0 million, compared to a net income of $14.5 billion in the prior year. Non-GAAP diluted loss per share in 2022 was $0.37, compared to an earnings of $74.67 per share in the prior year. Non-GAAP diluted loss per share in 2022, excluding the implementation of the Rights Agreement and the newly-issued common and preferred shares, would be $0.59 per share. Reconciliations of non-GAAP measures to the nearest comparable GAAP measures are included at the end of this earnings announcement. As of December 31, 2022, cash and cash equivalents and restricted cash totaled $4.3 billion, compared to $11.6 billion as of December 31, 2021. In 2022, net cash used in operating activities was $770.7 million, net cash used in investing activities was $5.8 billion, and net cash used in financing activities was $241.4 million. As of December 31, 2022, the Company had $0.3 million in bank loans due within one year. The Company expects that its current cash position will be able to support its operations for at least the next 12 months. Legal Proceedings As previously disclosed by the Company, on March 13, 2018, 1Globe Capital LLC (“1Globe”) filed a complaint against the Company in the Antigua Court. The trial of the matter took place from December 3 to 5, 2018. On December 19, 2018, the Antigua judge handed down his judgment (the “Antigua Judgment”), finding the Company fully in favor, dismissing 1Globe’s claim and declaring the Rights Agreement was validly adopted as a matter of Antigua law. On January 29, 2019, 1Globe filed a Notice of Appeal against the Antigua Judgment. On March 4, 2019, 1Globe filed an application for urgent interim relief, seeking an injunction to prevent the Company from continuing to implement its Rights Agreement until the resolution of the appeal. This application was heard on April 4, 2019, at which the Court of Appeal issued an order restraining the Company from operating the Rights Agreement in any way that affects 1Globe’s rights or shareholding or otherwise distributing the exchange shares to the Company’s shareholders who did not trigger the Rights Plan until after the determination of the appeal (the “Exchange Shares”). 1Globe’s appeal against the Antigua Judgment was heard on September 18, 2019, and the appeal decision was announced by the Eastern Caribbean Supreme Court, Court of Appeal (the “Court of Appeal”) on December 9, 2021, upholding the Antigua Judgment in each point. 1Globe applied for leave to appeal to the Judicial Committee of the Privy Council (the “Privy Council”), and the hearing of the application was held on February 24, 2022, in which the Court of Appeal granted 1Globe leave to appeal to the Privy Council on certain grounds, although not including the challenge to the validity of the Rights Agreement. On April 19, 2022, 1Globe renewed its application directly to the Privy Council for leave to appeal on its ground of appeal concerning the validity of the Rights Agreement. On July 13, 2022, 1Globe filed its Notice of Appeal on those grounds on which the Court of Appeal had granted 1Globe leave to appeal. On September 16, 2022, 1Globe filed an application to the Privy Council seeking permission to amend its existing application for permission to appeal and its existing Notice of Appeal, and to seek permission to appeal on another ground rejected by the Court of Appeal concerning the exercise of the Antigua Court’s discretion. The Company responded on October 21, 2022. On February 15, 2023, the Privy Council made a procedural decision to allow amendment of its existing application for permission to appeal, and decided to deal with procedural and substantive issues together at the Final Hearing. 1Globe has not yet taken steps to list a substantive hearing before the Privy Council. The appeal outcome is therefore pending. As previously disclosed, on March 5, 2018, the Company filed a lawsuit in the Court of Chancery of the State of Delaware, seeking a determination on whether 1Globe, the Chiang Li Family, OrbiMed Advisors, LLC and certain other shareholders of the Company had triggered the Rights Agreement. On April 12, 2018, 1Globe filed an amended answer to the Company’s complaint, counterclaims and a third-party complaint against the Company and Mr. Weidong Yin, alleging, among other allegations, that the Rights Agreement is not valid. On March 6, 2019, the Delaware Chancery Court entered a status quo order, providing that the Company not distribute any of the Exchange Shares to the Company’s shareholders who did not trigger the Rights Plan until the final disposition of the pending Delaware litigation or further order of the Court. On April 8, 2019, the Delaware Chancery Court stated that the Delaware litigation was pending the final outcome of 1Globe’s appeal of the Antigua Judgment. Separately, Heng Ren Investments LP (“Heng Ren”) filed suits against SINOVAC and Weidong Yin on May 31, 2019 in Massachusetts state court for the alleged breach of fiduciary duties and wrongful equity dilution. SINOVAC moved the matter from the state court to the United States District Court for the District of Massachusetts. Subsequently, on April 29, 2021, Heng Ren filed an amended complaint which alleged that Mr. Yin breached fiduciary duties owed to minority shareholders, that SINOVAC aided and abetted breaches of fiduciary duties and that both SINOVAC and Mr. Yin engaged in wrongful equity dilution. Heng Ren requested damages, attorney fees, and prejudgment interest. In July 2021, SINOVAC moved to dismiss Heng Ren’s amended complaint in the federal court in Massachusetts. On March 4, 2022, the court granted the motion as to the breach of fiduciary duty claims and denied the motion as to the wrongful equity dilution claim, and denied reconsideration of its decision on the motion. SINOVAC has answered the complaint. On July 2, 2018, the Company completed a private placement of its common shares with two private investors (the “PIPE Transaction”). On December 5, 2022, a purported shareholder filed a putative class action complaint in the United States District Court for the District of Massachusetts, asserting a claim under Section 204 of the Antigua and Barbuda International Business Corporations Act related to the PIPE Transaction, alleging that all shareholders were harmed in an identical manner to one another by the PIPE Transaction because the shares that were issued in the PIPE Transaction allegedly undervalued SINOVAC and all shareholders were purportedly wrongfully diluted as a result. The purported shareholder is represented by the same attorney who represents Heng Ren, and requests damages, attorneys’ fees, and prejudgment interest. On January 18, 2023, the Company filed a motion to dismiss in such purported shareholder’s matter (the “Motion to Dismiss”). On February 15, 2023, the court stayed discovery in the Heng Ren matter pending the resolution of the Motion to Dismiss. The Motion to Dismiss was fully briefed as of March 9, 2023, and is currently pending before the court. Status of Exchange Shares and Trading in the Company’s Shares As a result of the pending legal proceedings described above, the Exchange Shares are expected to remain in a trust for the benefit of the Company’s shareholders who did not trigger the Rights Plan until, at least, the conclusion of the appeal against the Antigua Judgement and the final disposition of the Delaware litigation or further order of the Delaware Chancery Court. The Exchange Shares remain issued and outstanding. The Nasdaq Stock Market LLC implemented a halt on trading of the Company’s common shares at the time the Exchange Shares were issued to the trust. The Company is currently unable to estimate when trading will resume, or if Nasdaq will take any additional action in regards to trading of the Company’s common shares. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, mumps, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalification requirements in 2017. The EV71 vaccine, Inlive®, is an innovative vaccine under "Category 1 Preventative Biological Products" and commercialized in China in 2016. In 2022, SINOVAC’s Sabin-strain inactivated polio vaccine (sIPV) and varicella vaccine were prequalified by the WHO. SINOVAC was the first company to be granted approval for its H1N1 influenza vaccine Panflu.1®, which has supplied the Chinese government's vaccination campaign and stockpiling program. The Company is also the only supplier of the H5N1 pandemic influenza vaccine, Panflu®, to the Chinese government stockpiling program. SINOVAC continually dedicates itself to new vaccine R&D, with more combination vaccine products in its pipeline, and constantly explores global market opportunities. SINOVAC plans to conduct more extensive and in-depth trade and cooperation with additional countries, and business and industry organizations. For more information, please visit the Company’s website at . Safe Harbor Statement This press release may include certain statements that are not descriptions of historical facts, but are forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates” and similar statements. Forward-looking statements involve risks, uncertainties and other factors that could cause actual results to differ materially from those contained in any such statements. In particular, the outcome of any litigation is uncertain, and the Company cannot predict the potential results of the litigation it filed or filed against it by others. Additionally, the triggering of a shareholder rights plan is nearly unprecedented, and the Company cannot predict the impact on the Company or its stock price as a result of the trigger of the rights plan. Non-GAAP Financial Measures To supplement its consolidated financial statements, which are prepared and presented in accordance with GAAP, SINOVAC uses the following non-GAAP financial measures: non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share. For more information on these non-GAAP financial measures, please refer to the table captioned “Reconciliations of non-GAAP Measures to the Nearest Comparable GAAP Measures” in this results announcement. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share help identify underlying trends in its business that could otherwise be distorted by the effect of certain income or expenses that SINOVAC includes in net income and diluted earnings (loss) per share. SINOVAC believes that non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share provide useful information about its core operating results, enhance the overall understanding of its past performance and future prospects and allow for greater visibility with respect to key metrics used by our management in its financial and operational decision-making. Non-GAAP adjusted EBITDA, non-GAAP net income (loss) and non-GAAP diluted earnings (loss) per share should not be considered in isolation or construed as an alternative to income from operations, net income (loss), diluted earnings (loss) per share, or any other measure of performance or as an indicator of SINOVAC’s operating performance. These non-GAAP financial measures presented here may not be comparable to similarly titled measures presented by other companies. Other companies may calculate similarly titled measures differently, limiting their usefulness as comparative measures to our data. Non-GAAP adjusted EBITDA represents net income (loss) and excludes interest and financing expenses, interest income, net other income and income tax benefit (expenses), and certain non-cash expenses, consisting of share-based compensation expenses, amortization and depreciation that SINOVAC does not believe are reflective of the core operating performance during the periods presented. Non-GAAP net income (loss) represents net income (loss) before share-based compensation expenses and foreign exchange gain or loss. Non-GAAP diluted earnings (loss) per share represents non-GAAP net income (loss) attributable to common shareholders divided by the weighted average number of shares outstanding during the periods on a diluted basis, including accounting for the effect of the assumed conversion of options. SINOVAC BIOTECH LTD. Consolidated Balance Sheets As of December 31, 2022 and 2021 (Expressed in thousands of U.S. Dollars) December 31, 2022 December 31, 2021 Current assets Cash and cash equivalents $ 4,278,124 $ 11,608,855 Restricted cash 8,253 10,905 Short-term investments 7,034,569 1,806,449 Accounts receivable - net 537,118 952,402 Inventories 180,719 375,511 Prepaid expenses and deposits 15,242 160,987 Income tax receivable 72,371 -- Total current assets 12,126,396 14,915,109 Property, plant and equipment – net 993,781 903,298 Prepaid land lease payments 69,815 39,730 Intangible assets - net 9,699 1,480 Long-term prepaid expenses 23 25 Long-term investments 661,440 655,835 Prepayments for acquisition of equipment 120,912 65,290 Deferred tax assets 71,118 52,031 Right-of-use assets 58,586 115,376 Other Non-current Assets 2,798 -- Total assets 14,114,568 16,748,174 Current liabilities Short-term bank loans and current portion of long-term bank loans 293 3,099 Loan from a non-controlling shareholder 4,358 1,582 Accounts payable and accrued liabilities 905,923 1,020,651 Income tax payable -- 1,267,504 Deferred revenue 17,955 79,941 Deferred government grants 15,120 12,559 Dividend payable 141,993 17,125 Lease liability 5,993 10,385 Total current liabilities 1,091,635 2,412,846 Deferred government grants 4,477 4,870 Long-term bank loans 11,513 12,668 Deferred tax liability 241,526 324,164 Loan from a non-controlling shareholder -- 4,708 Lease liability 52,516 112,465 Other non-current liabilities 240 444 Total long-term liabilities 310,272 459,319 Total liabilities 1,401,907 2,872,165 Commitments and contingencies Equity Preferred stock 15 15 Common stock 100 100 Additional paid-in capital 540,582 547,691 Subscriptions receivable -- (7,109) Accumulated other comprehensive income (loss) (383,276) 130,622 Statutory surplus reserves 1,538,013 1,514,297 Accumulated earnings 7,225,987 7,141,819 Total shareholders' equity 8,921,421 9,327,435 Non-controlling interests 3,791,240 4,548,574 Total equity 12,712,661 13,876,009 Total liabilities and equity $ 14,114,568 $ 16,748,174 SINOVAC BIOTECH LTD. Consolidated Statements of Comprehensive Income (Loss) For the six and twelve months ended 2022 and 2021 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended December 31 Year ended December 31, 2022 2021 2022 2021 (Unaudited) (Unaudited) Sales $ 280,471 $ 8,393,848 $ 1,492,761 $ 19,374,904 Cost of sales 430,094 440,455 684,456 1,072,221 Gross profit (149,623) 7,953,393 808,305 18,302,683 Selling, general and administrative expenses 667,663 428,510 823,543 591,167 Provision for doubtful accounts 3,461 3,528 4,268 2,967 Research and development expenses 257,714 101,129 442,108 155,040 Loss on disposal of property, plant and equipment 1,927 683 5,213 977 Government grants recognized in income (746) (39) (760) (725) Total operating expenses 930,019 533,811 1,274,372 749,426 Operating income (loss) (1,079,642) 7,419,582 (466,067) 17,553,257 Interest and financing expenses (641) (1,314) (1,264) (2,836) Interest income 106,820 71,764 190,818 102,568 Other income (expense), net 72,293 (88,999) 301,751 (89,948) Income (loss) before income taxes (901,170) 7,401,033 25,238 17,563,041 Income tax benefit (expense) 198,855 (1,534,196) 62,893 (3,104,130) Net income (loss) (702,315) 5,866,837 88,131 14,458,911 Less: (income) loss attributable to non-controlling interests 331,669 (2,507,683) 25,735 (5,991,431) Net income (loss) attributable to shareholders of Sinovac (370,646) 3,359,154 113,866 8,467,480 Preferred stock dividends (3,024) (3,024) (5,982) (5,982) Net income (loss) attributable to common shareholders of Sinovac (373,670) 3,356,130 107,884 8,461,498 Net income (loss) (702,315) 5,866,837 88,131 14,458,911 Other comprehensive income (loss), net of tax of nil Foreign currency translation adjustments (279,794) 162,103 (859,045) 193,098 Comprehensive income (loss) (982,109) 6,028,940 (770,914) 14,652,009 Less: comprehensive (income) loss attributable to non-controlling interests 445,656 (2,578,813) 370,882 (6,073,832) Comprehensive income (loss) attributable to shareholders of Sinovac (536,453) 3,450,127 (400,032) 8,578,177 Earnings (loss) per share Basic net income (loss) per share (3.76) 33.79 1.08 85.20 Diluted net income (loss) per share (3.76) 29.46 1.00 74.27 Weighted average number of shares of common stock outstanding Basic 99,502,243 99,328,085 99,502,243 99,311,551 Diluted 114,172,782 114,022,517 114,172,782 114,005,983 SINOVAC BIOTECH LTD. Consolidated Statements of Cash Flows For the six and twelve months ended 2022 and 2021 (Expressed in thousands of U.S. Dollars) Six months ended December 31 Year ended December 31, 2022 2021 2022 2021 (Unaudited) (Unaudited) Operating activities Net income (loss) $ (702,315) $ 5,866,837 $ 88,131 $ 14,458,911 Adjustments to reconcile net income to net cash provided by (used in) operating activities: Deferred income taxes (67,172) 335,990 (83,010) 265,096 Share-based compensation -- 6,223 -- 7,735 Inventory provision 83,800 68,700 140,004 70,133 Provision for doubtful accounts 3,461 3,528 4,268 2,967 Loss on disposal of property, plant and equipment 1,927 683 5,213 977 Depreciation of property, plant and equipment 78,660 67,920 153,819 84,446 Amortization of prepaid land lease payments 1,374 831 1,749 2,203 Amortization of intangible assets 932 94 1,029 183 Government grants recognized in income (746) (39) (760) (725) Changes in: Accounts receivable 429,615 423,635 289,600 (710,355) Inventories (6,869) (32,532) 30,382 (334,062) Income tax payable (191,672) (111,080) (1,275,296) 1,216,717 Prepaid expenses and deposits (111,395) (100,859) 22,519 (143,324) Deferred revenue (13,364) (255,923) (58,485) (288,779) Accounts payable and accrued liabilities 536,063 (8,173) (86,860) 720,858 Other non-current liabilities (5,531) (431) (3,048) (440) Net cash provided by (used in) operating activities 36,768 6,265,404 (770,745) 15,352,541 Financing activities Proceeds from bank loans 1 165 151 13,511 Repayments of bank loans (48) (19,534) (2,981) (33,436) Proceeds from issuance of common stock, net of share issuance costs -- 996 -- 1,033 Dividend paid (260,702) (1,838,094) (263,171) (1,875,892) Proceeds from subsidiary's financing -- -- 11,291 -- Government grants received 9,776 3,082 14,797 4,317 Loan from a non-controlling shareholder -- 9 -- 7,119 Repayments of loan from a non-controlling shareholder (1,474) (13,307) (1,486) (13,332) Net cash used in financing activities (252,447) (1,866,683) (241,399) (1,896,680) Investing activities Purchase of investments (5,717,991) (4,446,838) (11,658,465) (8,826,611) Proceeds from redemption of investments 3,619,956 5,018,775 6,327,521 6,567,491 Proceeds from disposal of equipment 5 120 608 172 Prepaid land lease payments (26,025) (18,596) (35,683) (30,986) Acquisition of intangible assets (9,568) (154) (9,568) (154) Purchase of equity investments (42,155) (13,663) (105,435) (13,663) Purchase of property, plant and equipment (114,402) (288,338) (393,800) (719,823) Proceeds from dissolution of subsidiary 114,352 -- 114,352 -- Net cash provided by (used in) investing activities (2,175,828) 251,306 (5,760,470) (3,023,574) Effect of exchange rate changes on cash and cash equivalents and restricted cash (189,210) 113,373 (560,769) 137,269 Increase (decrease) in cash and cash equivalents and restricted cash (2,580,717) 4,763,400 (7,333,383) 10,569,556 Cash and cash equivalents and restricted cash, beginning of period 6,867,094 6,856,360 11,619,760 1,050,204 Cash and cash equivalents and restricted cash, end of period 4,286,377 11,619,760 4,286,377 11,619,760 SINOVAC BIOTECH LTD. Reconciliations of Non-GAAP measures to the nearest comparable GAAP measures For the six and twelve months ended 2022 and 2021 (Expressed in thousands of U.S. Dollars, except for numbers of shares and per share data) Six months ended December 31 Year ended December 31, 2022 2021 2022 2021 (Unaudited) (Unaudited) (Unaudited) (Unaudited) Net income (loss) $ (702,315) $ 5,866,837 $ 88,131 $ 14,458,911 Adjustments: Share-based compensation -- 6,223 -- 7,735 Depreciation and amortization 80,966 68,845 156,597 86,832 Interest and financing expenses, net of interest income (106,179) (70,450) (189,554) (99,732) Other expense (income), net (72,293) 88,999 (301,751) 89,948 Income tax expense (198,855) 1,534,196 (62,893) 3,104,130 Non-GAAP adjusted EBITDA (998,676) 7,494,650 (309,470) 17,647,824 Net income (loss) (702,315) 5,866,837 88,131 14,458,911 Add: Foreign exchange (gain) loss (103,472) 73,179 (265,091) 68,026 Add: Share-based compensation -- 6,223 -- 7,735 Non-GAAP net income (loss) (805,787) 5,946,239 (176,960) 14,534,672 Net income (loss) attributable to common shareholders of Sinovac (373,670) 3,356,130 107,884 8,461,498 Add: Preferred stock dividends 3,024 3,024 5,982 5,982 Net income (loss) attributable to common shareholders of Sinovac for computing diluted earnings per share (370,646) 3,359,154 113,866 8,467,480 Add: Non-GAAP adjustments to net income (61,239) 46,868 (156,332) 45,038 Non-GAAP net income (loss) attributable to common shareholders of Sinovac for computing non-GAAP diluted earnings per share (431,885) 3,406,022 (42,466) 8,512,518 Weighted average number of shares on a diluted basis 114,172,782 114,022,517 114,172,782 114,005,983 Diluted earnings (loss) per share (3.76) 29.46 1.00 74.27 Add: Non-GAAP adjustments to net income (loss) per share (0.54) 0.41 (1.37) 0.40 Non-GAAP diluted earnings per share (4.30) 29.87 (0.37) 74.67 View source version on businesswire.com: Contacts Sinovac Biotech Ltd. Helen Yang Tel: +86-10-8279 9720 Email: ir@sinovac.com Source: Sinovac Biotech Ltd. View this news release online at: